← Leaderboards
Nathan Edward Reticker-Flynn
Stanford University
$1,662,491
Attributed
$1,740,500
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $629.5K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,740,500 · 3
By mechanism
DP2$1,420,756 · 1
F32$163,726 · 1
U01$156,018 · 1
Top collaborators
- Monte Meier Winslow1 shared
Most similar at Stanford University
Same institution · by research overlap
- Samuel Strober$36,157,957
- Edgar G. Engleman$35,389,843
- Sylvia Katina Plevritis$44,733,712
- Bali Pulendran$71,035,530
- Robert S Negrin$29,816,136
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsImmuneTumorImmune ResponsePreventProductionImmune ToleranceHomeostasisUnited StatesImmunotherapySiteAntigen-Presenting CellsAntigensCancer ImmunotherapyCellsCytokineDisseminated Malignant NeoplasmGenerationsNeoplasm MetastasisAntigen PresentationAdaptive Immune ResponseResolutionGenome EngineeringEnvironment
Grant awards (7)
A modular cell therapy platform for controlling immunological tolerance$473,515
DP2 · FY2025 · AI · contact PI
A modular cell therapy platform for controlling immunological tolerance$473,515
DP2 · FY2024 · AI · contact PI
Genetic analysis of aging on immune responses to lung cancer$156,018
U01 · FY2024 · AG
A modular cell therapy platform for controlling immunological tolerance$473,726
DP2 · FY2023 · AI · contact PI
Development of a glycopeptide vaccine for cancer metastasis$58,002
F32 · FY2016 · CA · contact PI
Development of a glycopeptide vaccine for cancer metastasis$54,194
F32 · FY2015 · CA · contact PI
Development of a glycopeptide vaccine for cancer metastasis$51,530
F32 · FY2014 · CA · contact PI